Back

Beneficial effects of treatment with a soluble guanylate cyclase stimulator on cardiac function and mitochondrial activity in an animal model of early-stage HFpEF

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Basic concepts in heart failure Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr Xocas Vazquez-Abuin

Santiago De Compostela (Spain)

5 More presentations in this session

Presentation thumbnail
Effect of qiliqiangxin according to N-terminal pro-B-type natriuretic peptide in patients with heart failure and reduced ejection fraction: insights from QUEST
Doctor L. Shen (Glasgow, CN)
Abstract Slides Video
Presentation thumbnail
Feasibility of a novel implantable device to provide heart failure therapy and left atrial pressure monitoring in a chronic animal study
Doctor S. Ge (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Amyloid-beta metabolism, cardiac remodeling and myocardial recovery in advanced heart failure
Doctor G. Zervas (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Xanthine oxidase inhibitors in cardiovascular disease: impact on mortality and ATP dynamics
Associate Professor M. Kuwabara (Shimotsuke, JP)
Abstract Slides Video
Presentation thumbnail
Myeloid-specific Nrf2 deletion increases fibrosis and contributes to the development of heart failure after murine myocardial infarction
Miss T. Ali (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Basic concepts in heart failure

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Effects of sacubitril-valsartan alone or in combination with dapagliflozin on aging-related heart failure with preserved ejection fraction
thumbnail
Congress Presentation
Effects of LCZ696 on lipid metabolism in an animal model of heart failure with preserved ejection fraction (HFpEF). Possible implications for the management of obesity associated with HFpEF.
thumbnail
Congress Presentation
Combination of an oral H2S donor to dapagliflozin provides additional therapeutic benefit in a cardiorenal model of heart failure with preserved ejection fraction (HFpEF)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources